PMC9300850_01
(A-F, H) Pathological and immunohistochemical staining of gastric cancer biopsy specimens from this patient. (A) Gastric adenocarcinoma (hematoxylin and eosin). (B) The tumor cells were strongly positive (3+) for HER2/neu immunostain. The expression of MLHI (C), MSH2 (D), MSH6 (E), and PMS2 (F) was preserved in tumor cells. (G)There were no tumor cells in the pelvic effusion. (H) showed positivity for PD-LI CPS 60.
fimmu-13-926740-g001.jpg
PMC9300850_01_fimmu-13-926740-g001.jpg
f1
Postoperative pathology revealed gastric adenocarcinoma with regional lymph nodes metastasis, pT3N3bM0 (p-Stage IIIC), with immunohistochemistry (IHC) HER2 (3+), pMMR (MLH1 (+), MSH2 (+), MSH6 (+), PMS2 (+) ( Figures 1A-F ). We then conducted an ultrasound puncture of the pelvic effusion, but no tumor cells were found in the effusion ( Figure 1G ). Immunohistochemical staining of the tumor tissue showed that the PD-L1 combined positive score (CPS) 60 ( Figure 1H ). PET-CT scans were evaluated during the maintenance therapy on 10 June 2021, complete response (CR) with the RECIST v1.1 was assessed ( Supplementary Figures 1A-C ).
Timeline of the whole treatment process for the patient. The patient experienced PD with the new emergence of enlarged paratracheal lymph nodes during postoperative adjuvant chemotherapy on 26 August 2020. Two months after apatinib was combined with chemotherapy, the subcarinal LN, right upper paratracheal LN, and left lower paratracheal LN were detected by CT scan on 06 November 2020, and the patient developed PI) again, After 4 cycles of PRaG therapy, the sum of diameters of the unirradiated target metastases decreased by 45% from baseline, and the right upper paratracheal LN almost disappeared. The patient was assessed as PR on 24 March 2021.18F FDG PET-CT on 10 June 2021, most LNs disappeared and one shrunk to normal size with normal FDG uptake. Therefore the patient achieved CR. Although the patient unfortunately suffered PD again on 21 January 2022 (new metastatic LNs appeared), he obtained 14 months of PFS from the start of PRaG therapy on 19 November 2020. PRaG therapy: The patient was treated with subcutaneous GM-CSF (200 gg once daily, d4-17) after the completion of radiotherapy (15Gy/3f, d1-3) and received a PD-I inhibitor (toripalimab 240mg, d4.The PRaG regimen was repeated every three weeks, and different mediastinal lymph nodes were irradiated during the PRaG treatment, with each cycle delivered to one metastatic site. After four cycles of PRaG therapy, maintenance treatment ofPD-1 monotherapy was administered every three weeks. Until 21 January 2022, when the patient suffered PD again, Each cycle of the above has a duration of 21 days. LN, lymph node; PD, progressive disease; PR, partial response; CR, complete response; PFS, progression-free survival.
fimmu-13-926740-g002.jpg
PMC9300850_01_fimmu-13-926740-g002.jpg
f2
The patient got complete response on 10 June 2021 ( Figure 2 ).
Trends of CEA and CA724 levels. The CA724 level was reduced to normal on 07 January 2021 after 2 cycles of PRaG therapy. The CEA level was decreased to normal on 22 March 2021 after 4 cycles of PRaG therapy. There was a fluctuating increase in both biomarkers from 6 August 2021 to 3 1 December 2021, but the disease remained stable after CT evaluation. On 20 January 2022, a multifold increase in the two biomarkers was detected, at which time the patient was assessed as progressive disease (PD) by CT scans.
fimmu-13-926740-g003.jpg
PMC9300850_01_fimmu-13-926740-g003.jpg
f3
Serum CEA and CA724 levels were measured every cycle ( Figure 3 )and an imaging assessment was performed every two cycles.
CT scans before (2020-11.06), during (2021-01-08), and after (2121-03-24, 2021-05-12) the PRaG therapy. Right upper paratracheal (A) and subcarinal lymph node (B) were the two irradiated lesions that gradually shrunk significantly after the PRaG therapy, One of the left lower paratracheal lymph nodes (C) progressively shrunk and the other (D) rapidly shrunk and disappeared after PRaG therapy. (E) shows that pelvic effusion gradually decreased and disappeared, The yellow arrow indicated the irradiated lesions, and the blue arrow indicated the unirradiated ones; all assessed lesions were circled with orange lines.
fimmu-13-926740-g004.jpg
PMC9300850_01_fimmu-13-926740-g004.jpg
f4
Both irradiated and unirradiated sites got progressive shrinkage during the treatment ( Figures 4A-D ). The ECOG performance status score changed from 2 to 0, with increased appetite, improved hypoproteinemia, and diminished pelvic effusion ( Figure 4E ).